§ 01 Overview
Overview
Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema).
Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.
§ 02 Mechanism
Mechanism of action
Cagrilintide is an acylated amylin analog with extended half-life. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and increase satiety via area postrema signaling.
- 01Additive weight loss when combined with GLP-1 agonists
- 02Reduced food cravings and portion size
- 03Preserved lean mass in some trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 0.16 – 2.4 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate alongside GLP-1 if stacked.
§ 04 Evidence
Evidence & research
Phase II monotherapy and CagriSema Phase III (REDEFINE) reported in 2024–2025 with ~22% weight loss in key arms.
FDA Status
Investigational as monotherapy; CagriSema in Phase III.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
'Cagrilintide·Semaglutide' Shown to Improve Blood Sugar in Diabetes Patients - 헬스조선
'Cagrilintide·Semaglutide' Shown to Improve Blood Sugar in Diabetes Patients 헬스조선
Novo’s next-gen weight-loss drug outperforms Zepbound in new trial - NewsNation
Novo’s next-gen weight-loss drug outperforms Zepbound in new trial NewsNation
Phase 3 Data Show CagriSema Drives Significant Weight Loss - Psychiatry Advisor
Phase 3 Data Show CagriSema Drives Significant Weight Loss Psychiatry Advisor
Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients Taking Basal Insulin - DocWireNews
Cagrilintide-Semaglutide Could Improve Glycemic Control in Type 2 Diabetes Patients Taking Basal Insulin DocWireNews
ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes - Medical Xpress
ADA: Once-weekly cagrilintide + semaglutide promising in type 2 diabetes Medical Xpress
Cellular loci for cagrilintide action identified - Nature
Cellular loci for cagrilintide action identified Nature
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance - Nature
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Nature
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials - Hamarsheh - 2026 - Endocrinology, Diabetes & Metabolism - Wiley Online Library
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials - Hamarsheh - 2026 - Endocrinology, Diabetes & Metabolism Wiley Online Library
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
International · 1
Trident Peptides
1,299+ Trustpilot reviews (5-star). Strongest review base in UK research peptides. No visible ISO/GMP; COAs not posted.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Appetite suppression can be substantial
Contraindications
None specified.
§ 10 Questions
Cagrilintide FAQ
- What is Cagrilintide?
- Long-acting amylin analog that slows gastric emptying and enhances satiety, typically paired with semaglutide (CagriSema). Cagrilintide is an acylated amylin analog with extended half-life. It acts on amylin and calcitonin receptors to slow gastric emptying, suppress glucagon, and increase satiety via area postrema signaling.
- What is Cagrilintide used for?
- Reported uses include additive weight loss when combined with glp-1 agonists, reduced food cravings and portion size, and preserved lean mass in some trials. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Cagrilintide dosed?
- Commonly referenced dosing is 0.16 – 2.4 mg weekly, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Cagrilintide?
- Commonly reported side effects include nausea and appetite suppression can be substantial. This list is not exhaustive.
- Is Cagrilintide legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational as monotherapy; CagriSema in Phase III..